Ionetix to provide Bayer with Therapeutic Radioisotope Actinium-225 (Ac-225)
“We recognized the emerging demand and made the early investment to develop a commercial-scale production solution for Ac-225 using our expertise in cyclotron accelerator and target technology,” said David Eve, VP of Medical Affairs for Ionetix Corporation. Located in Lansing, Michigan, Ionetix has established a new isotope production facility that is dedicated to manufacturing alpha-emitters. The first cyclotron was commissioned at the facility earlier this year and installation of a second cyclotron is planned for 2024. Both cyclotrons will be used to produce alpha-emitters, providing both onsite redundancy and increased capacity to scale output. Distribution of GMP grade, n.c.a. Ac-225 will begin in early 2024.
Share:
More News
Thomas Guérinier, CEO and Co-founder of Inside Therapeutics: “The collaboration with OSE and MiNT provides us with a fantastic opportunity to demonstrate the uniqueness of our technology for the development of mRNA therapies from early development through to clinical trials and GMP production. The HexARN project fits perfectly with our
Thomas Mehrling, MD, PhD, CEO and Director of Helix, said “As co-founder of the Laevoroc companies, I’ve had the privilege of seeing LEUMUNA and GEMCEDA evolve from early scientific concepts into differentiated, first-in-class therapeutic candidates with real potential to transform cancer care. Their integration into Helix marks a strategic consolidation
“At Boundless, we’re committed to delivering innovative therapies for patients with oncogene-amplified cancers through disciplined execution,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “By prioritizing the novel combination of BBI-355 and BBI-825, along with our exciting Kinesin program, BBI-940, we’re concentrating our resources where we see
